INmune Bio, Inc. (NASDAQ:INMB) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of INmune Bio, Inc. (NASDAQ:INMB) have been given a consensus rating of “Moderate Buy” by the seven brokerages that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $18.40.

INMB has been the subject of several analyst reports. Wall Street Zen lowered INmune Bio from a “hold” rating to a “sell” rating in a research note on Saturday, August 2nd. Scotiabank reaffirmed a “sector underperform” rating on shares of INmune Bio in a research note on Tuesday, July 1st. Raymond James Financial downgraded shares of INmune Bio from a “moderate buy” rating to a “hold” rating in a report on Monday, June 30th. BTIG Research reaffirmed a “neutral” rating on shares of INmune Bio in a research report on Tuesday, July 1st. Finally, Maxim Group decreased their price target on shares of INmune Bio from $30.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, July 2nd.

INmune Bio Price Performance

NASDAQ:INMB opened at $2.40 on Wednesday. The firm has a market cap of $63.80 million, a PE ratio of -0.97 and a beta of 0.97. The firm has a 50 day simple moving average of $3.68 and a 200-day simple moving average of $6.45. INmune Bio has a 1-year low of $1.89 and a 1-year high of $11.64.

INmune Bio (NASDAQ:INMB) last released its earnings results on Thursday, August 7th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.03. As a group, sell-side analysts expect that INmune Bio will post -2.24 earnings per share for the current fiscal year.

Institutional Investors Weigh In On INmune Bio

A number of institutional investors have recently added to or reduced their stakes in INMB. Raymond James Financial Inc. acquired a new position in shares of INmune Bio in the 4th quarter valued at about $2,221,000. Dauntless Investment Group LLC purchased a new stake in INmune Bio during the fourth quarter worth approximately $896,000. XTX Topco Ltd increased its position in shares of INmune Bio by 240.9% in the second quarter. XTX Topco Ltd now owns 125,847 shares of the company’s stock worth $291,000 after acquiring an additional 88,928 shares in the last quarter. Millennium Management LLC raised its stake in shares of INmune Bio by 43.9% in the 4th quarter. Millennium Management LLC now owns 291,327 shares of the company’s stock valued at $1,360,000 after acquiring an additional 88,823 shares during the period. Finally, Renaissance Technologies LLC raised its stake in shares of INmune Bio by 73.3% in the 4th quarter. Renaissance Technologies LLC now owns 185,800 shares of the company’s stock valued at $868,000 after acquiring an additional 78,600 shares during the period. Hedge funds and other institutional investors own 12.72% of the company’s stock.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.